Olumiant® (Baricitinib)

Para consultar la información para prescribir completa de Olumiant® (Baricitinib) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Baricitinib: Efficacy and Safety in Patients with Comorbid Demyelinating Disorders

Analyses of the efficacy and safety of BARI in patients with moderate to severe RA and comorbid demyelinating disorders have not been conducted.


Exclusion Criteria Related to Demyelinating Disorders in the Baricitinib Clinical Trials

Demyelinating disorders, as defined by the Standardized MedDRA Demyelination Query (SMQ) 20000154 narrow preferred terms, were not specific exclusion criteria in the 4 phase 3 BARI clinical trials, RA-BEAM, RA-BEACON, RA-BUILD, and RA-BEGIN. However, patients were excluded if they had a history or presence of a serious or unstable illness that, in the opinion of the investigator, could

  • constitute a risk when taking an investigational product, or
  • interfere with the interpretation of data.1

See Standardized MedDRA Demyelination Query (SMQ) 20000154 Narrow Preferred Terms for a listing of the narrow preferred terms used to define demyelinating disorders.

Standardized MedDRA Demyelination Query (SMQ) 20000154 Narrow Preferred Terms1

Acute disseminated encephalomyelitis

Marchiafava-Bignami disease

Acute haemorrhagic leukoencephalitis

Multiple sclerosis

Anti-myelin –associated glycoprotein associated polyneuropathy

Multiple sclerosis relapse

Autoimmune demyelinating disease

Multiple sclerosis relapse prophylaxis

Chronic inflammatory demyelinating polyradiculoneuropathy

Myelitis transverse

Clinically isolated syndrome

Myoclonic epilepsy and ragged-red fibres

Concentric sclerosis

Neuromyelitis optica spectrum disorder

Demyelinating polyneuropathy

Neuropathy, ataxia, retinitis pigmentosa syndrome


Noninfectious myelitis

Encephalitis periaxialis diffusa

Noninfective encephalomyelitis


Optic neuritis

Expanded disability status scale score decreased

Osmotic demyelination syndrome

Expanded disability status scale score increased

Primary progressive multiple sclerosis

Guillain-Barre syndrome

Progressive multifocal leukoencephalopathy

Hypergammaglobulinaemia benign monoclonal

Progressive multiple sclerosis


Progressive relapsing multiple sclerosis


Relapsing-remitting multiple sclerosis

Lewis-Summer syndrome

Secondary progressive multiple sclerosis

MELAS syndrome

Toxic leukoencephalopathy

Marburg’s variant multiple sclerosis

Tumefactive multiple sclerosis

Patients with Comorbid Demyelinating Disorders

None of the patients treated with BARI had a pre-existing condition or historical diagnosis of demyelinating disorders in the 4 phase 3 BARI clinical trials.1

Clinical Recommendations For Patients with Demyelinating Disorders

Lilly cannot provide a recommendation on whether to use BARI in a patient with demyelinating disorders. The treating physician may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors, in formulating an assessment and approach. The treating physician should consider potential risks and benefits of treatment options, and monitor appropriately.


1Data on file, Eli Lilly and Company and/or one of its subsidiaries.


BARI = baricitinib

MedDRA = Medical Dictionary for Regulatory Activities

RA = rheumatoid arthritis

Fecha de la última revisión: 2020 M08 31

Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta